Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy

Objectives: Chemotherapy-induced thrombocytopenia seems to be a relevant problem and the risk of clinical bleeding in patients with gynecologic malignancy is reported to be higher than other malignancy. In this study, the authors investigated chemotherapy-induced thrombocytopenia recently performed in all patients with gynecologic malignancy. Materials and Methods: Between January 2009 and December 2011, the authors examined reported chemotherapy-induced thrombocytopenia using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. They analyzed the incidence and clinical features of chemotherapy-induced thrombocytopenia in patients with gynecologic malignancy. Results: During this period they administered over 1,614 infusions (29 regimens) to 291 patients. Chemotherapyinduced thrombocytopenia occurred in 43 (14.8%) patients over 56 (3.5%) chemotherapy cycles. Bleeding occurred in 13 (4.5%) patients over 14 (0.9%) cycles. Platelet transfusions were administered for eight (2.7%) patients over eight (0.5%) cycles. Median platelet count at platelet transfusions was 17,000 /μl. Chemotherapy-induced thrombocytopenia was associated with more than five previous chemotherapy cycles, previous radiotherapy, disseminated disease, distant metastatic disease, poor performance status, and taxane-including regimens. Clinical bleeding was associated with previous radiotherapy, distant metastatic disease, poor performance status, and taxane-including regimens. Conclusions: Estimating bleeding risk factor such as previous radiotherapy, distant metastatic disease, poor performance status, and taxane-including regimens seem to be important for safe management of chemotherapy-induced thrombocytopenia.

Chemotherapy-induced thrombocytopenia; Clinical bleeding; Gynecologic malignancy.

[1] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D., et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[2] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[3] Schiffer C.A., Anderson K.C., Bennett C.L., Bernstein S., Elting L.S., Goldsmith M., et al.: “Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology”. J. Clin. Oncol., 2001, 19, 1519.

[4] Gary L.G., Darlene G.G., Harriet O.S., Carol D.V., Carolyn D.R., Edward R.B.: “Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer”. J. Clin. Oncol., 1994, 12, 2317.

[5] Gaydos A.L., Freireich E.J., Manel N.: “The quantitative relation between platelet count and hemorrhage in patients with acute leukemia”. N. Engl. J. Med., 1962, 266, 905.

[6] Elting L.S., Rubenstein E.B., Martin C.G., Kurtin D., Rodriguez S., Laiho E., Kanesan K., et al.: “Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia”. J. Clin. Oncol., 2001, 19, 1137.

[7] Elting L.S., Martin C.G., Kurtin D., Cantor S.B., Rubenstein E.B., Rodriguez S., et al.: “The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors”. Cancer, 2002, 94, 3252.

[8] Heckman K.D., Weiner G.J., Davis C.S., Strauss R.G., Jones M.P., Burns C.P.: “Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/ml versus 20,000/ml”. J. Clin. Oncol., 1997, 15, 1143.

[9] Rebulla P., Finazzi G., Marangoni F., Awisati G., Gugliotta L., Tognoni G., et al.: “The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia”. N. Engl. J. Med., 1997, 337, 1870.

[10] Wandt H., Frank M., Ehninger G., Schneider C., Brack N., Daoud A., et al.: “Safety and cost effectiveness of a 10 x 109/L trigger for prophylactic platelet transfusions compared with 20 x 109/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia”. Blood, 1998, 91, 3601.

[11] Hitron A., Steinke D., Sutphin S., Lawson A., Talbert J., Adams V.: “Incidence and risk factors of clinically significant chemotherapyinduced thrombocytopenia in patients with solid tumors”. J. Oncol. Pharm. Pract., 2011, 17, 312.